|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have developed a fully human, second-generation CAR directed against the envelope protein of hepatitis B virus on the surface of infected cells (S-CAR).
|
30852138 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Structure-Guided Approach to Identify Potential Inhibitors of Large Envelope Protein to Prevent Hepatitis B Virus Infection.
|
31772697 |
2019 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we show that a viral membrane protein, the duck hepatitis B virus (DHBV) large envelope protein (DHBs L), produced by WG-CFPS, is phosphorylated upon translation at the same sites as DHBs L produced during DHBV infection of primary hepatocytes.
|
31850370 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the aa 158 sequence determined attachment of the HBV envelope protein to the host cell, demonstrating the mechanism whereby HBV infection would create positive selection at this NTCP residue.
|
30541857 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we modified synthetic lipid-based nanoparticles with targeting peptides derived from the hepatitis B virus large envelope protein (HBVpreS) to specifically target the sodium-taurocholate cotransporting polypeptide (NTCP; <i>SLC10A1</i>) on the sinusoidal membrane of hepatocytes.
|
31333191 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel T-cell epitope in the transmembrane region of the hepatitis B virus envelope protein responds upon dendritic cell expansion.
|
30415392 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is the first report on the mechanisms of HBV envelope protein transport among the organelles, and the results provide important insights into the therapeutic control of HBV infection.
|
31118260 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, specific domains and residues in the HBV S protein that are required for oligomerization and SVP generation were defined.<b>IMPORTANCE</b> The small hepatitis B virus envelope protein S has the intrinsic ability to direct the morphogenesis of spherical 20-nm subviral lipoprotein particles.
|
29540592 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, we compared the antibody production patterns of HIV-1 Env gp120 and hepatitis B virus surface antigen (HBsAg) to provide insights into how we may improve the protective efficacy of Env-based immunogens.
|
30569292 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of immune escape mutations and N-linked glycosylation on the secretion of hepatitis B virus virions and subviral particles: Role of the small envelope protein.
|
29604477 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Synthesis and assembly of Hepatitis B virus envelope protein-derived particles in Escherichia coli.
|
28601634 |
2017 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Characterization of contrasting features between hepatitis B virus genotype A and genotype D in small envelope protein expression and surface antigen secretion.
|
28126637 |
2017 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have constructed and clinically evaluated a hypoallergenic vaccine for grass pollen allergy, BM32, which is based on fusion proteins consisting of peptides from the IgE binding sites of the major grass pollen allergens fused to preS (preS1+preS2), a domain of the hepatitis B virus (HBV) large envelope protein which mediates the viral attachment and entry.
|
27568223 |
2016 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hepatitis B surface antigen envelope protein protects the HDV nucleocapsid antigen and provides a means for the virus to enter and exit the hepatocyte.
|
26327754 |
2015 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Australian antigen, the envelope protein of hepatitis B virus (HBV), was discovered in 1967 as a prevalent serum antigen in hepatitis B patients.
|
25833941 |
2015 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
For the patients who showed viremia, we analyzed amino acid sequences of the HB envelope protein, and we performed a statistical analysis for the factors associated with viremia.
|
24961506 |
2014 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
NTCP also functions as a cellular receptor for viral entry of hepatitis B virus (HBV) and hepatitis D virus (HDV) through a specific interaction between NTCP and the pre-S1 domain of HBV large envelope protein.
|
24390325 |
2014 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Modification of the hepatitis B virus envelope protein glycosylation pattern interferes with secretion of viral particles, infectivity, and susceptibility to neutralizing antibodies.
|
24899172 |
2014 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using synthetic lipopeptides derived from the HBV envelope protein, we previously demonstrated prevention of de novo HBV infection in vivo.
|
23246506 |
2013 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Non-detection of hepatitis B virus (HBV) envelope protein (hepatitis B surface antigen, HBsAg) in a chronically HBV infected individual has been described as occult infection.
|
24135177 |
2013 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Natural variation and mutations in the envelope protein (S) of hepatitis B virus can translate into HBsAg variants no longer detectable by conventional HBsAg assays.
|
22296790 |
2012 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site.
|
20881037 |
2010 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes.
|
18297057 |
2008 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The N-terminal pre-S domain of the large hepatitis B virus (HBV) envelope protein plays a pivotal role at the initial step of the viral entry pathway.
|
17376925 |
2007 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects.
|
17045504 |
2006 |